Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

Rang in Aktien #3273
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Aktienkurs
$118.49
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$5.39B
Veränderung (1 Tag)
-2.43%
Veränderung (1 Jahr)
135.75%
Land
US
Handel Haemonetics Corporation (HAE)

Kategorie

Healthcare
Operative Marge für Haemonetics Corporation (HAE)
Operative Marge zum October 2026 TTM: 18.18%
Laut den neuesten Finanzberichten und dem Aktienkurs von Haemonetics Corporation beträgt die aktuelle operative Marge (TTM) 18.18%. Am Ende des Jahres 2024 lag die operative Marge bei 12.60%.
Historie der operativen Marge von Haemonetics Corporation von 2000 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) 18.18% 11.53%
2025 16.30% 29.37%
2024 12.60% -5.62%
2023 13.35% 64.21%
2022 8.13% 22.07%
2021 6.66% -57.23%
2020 15.57% 80.42%
2019 8.63% 38.97%
2018 6.21% -383.56%
2017 -2.19% -54.75%
2016 -4.84% -208.76%
2015 4.45% -11.71%
2014 5.04% -20.38%
2013 6.33% -48.07%
2012 12.19% -25.40%
2011 16.34% 26.67%
2010 12.90% -9.85%
2009 14.31% 5.14%
2008 13.61% -2.51%
2007 13.96% -40.82%
2006 23.59% 50.93%
2005 15.63% 24.05%
2004 12.60% 13.31%
2003 11.12% -2.37%
2002 11.39% 149.23%
2001 4.57% -62.23%
2000 12.10% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
17.03% -99.06%
US
17.86% -99.02%
IE
22.03% -98.79%
US
21.46% -98.82%
US
0.00% -
DE
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.